RIMI   Report issue

For profit Phase 3
Founded: Oslo Norway (1977)
Status: Left NME R&D (2007)

Organization Overview

First Clinical Trial
1997
NCT00764010
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1997

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

icosapent ethyl (vascepa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atherosclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1